

REMARKS

The specification has been amended to correct errors in Example 2 and clarify that clotrimazole is the active and caprylyl pyrrolidone is the solvent in the formulation of Example 2. Clotrimazole is a preferred active (see e.g. page 5), and caprylyl pyrrolidone is a common solvent to the formulations of Examples 1-9. No new matter has been added.


Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "**Version with markings to show changes made**".

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 468452000200.

Respectfully submitted,

Dated: August 7, 2002

By:


Cameron A. King
Registration No. 41,897

Morrison & Foerster LLP
425 Market Street
San Francisco, California 94105-2482
Telephone: (415) 268-6524
Facsimile: (415) 268-7522

VERSION WITH MARKINGS TO SHOW CHANGES MADE**In the Specification:**

The table on page 7, titled "Example 1" has been amended as follows:

Ingredient	Class	% W/W
<u>Clotrimazole</u> [Caprylyl pyrrolidone]	Pharmaceutical active	2
<u>Caprylyl pyrrolidone</u> [Surfadone LP 100]	Solvent	10
PEG 400	Organic bulking agent	60.5
Hydroxypropycellulose	Thickening agent	4
Cocamidopropyl Betaine	Surfactant/booster	2.5
Sodium Cocoamphacetate	Mild surfactant	4
Sodium Lauryl Ether Sulfate	Detergent	7
Ammonium Lauryl Sulfate	Detergent	10